



October 14, 2021

Argon Medical Devices, Inc.  
Scott Bishop  
Senior Regulatory Affairs Specialist  
1445 Flat Creek Road  
Athens, Texas 75751

Re: K213002

Trade/Device Name: SCORPION Portal Vein Access Set  
Regulation Number: 21 CFR 870.1340  
Regulation Name: Catheter Introducer  
Regulatory Class: Class II  
Product Code: DYB  
Dated: September 17, 2021  
Received: September 20, 2021

Dear Scott Bishop:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or

postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email ([DICE@fda.hhs.gov](mailto:DICE@fda.hhs.gov)) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

For  
Misti Malone  
Assistant Director  
DHT2C: Division of Coronary  
and Peripheral Intervention Devices  
OHT2: Office of Cardiovascular Devices  
Office of Product Evaluation and Quality  
Center for Devices and Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known)

K213002

Device Name

Scorpion® Portal Vein Access Set

Indications for Use (Describe)

The Scorpion Portal Vein Access Set is intended for transjugular liver access in diagnostic and interventional procedures.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

**CONTINUE ON A SEPARATE PAGE IF NEEDED.**

This section applies only to requirements of the Paperwork Reduction Act of 1995.

**\*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\***

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services  
Food and Drug Administration  
Office of Chief Information Officer  
Paperwork Reduction Act (PRA) Staff  
[PRASStaff@fda.hhs.gov](mailto:PRASStaff@fda.hhs.gov)

*"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."*

## 510(k) Summary

**Date Prepared:** September 16, 2021

---

**Company:** Argon Medical Devices, Inc.  
1445 Flat Creek Road  
Athens, Texas 75751 USA  
Facility Registration number: 1625425

**Contact:** Scott Bishop  
Senior Manager, Regulatory Affairs  
Phone: 469-430-0546  
Fax: 469-731-1480  
Email: [scott.bishop@argonmedical.com](mailto:scott.bishop@argonmedical.com)

---

**Device Trade Name:** Scorpion® Portal Vein Access Set

**Device Common Name:** Catheter Introducer

**Device Classification:** Introducer, Catheter  
Product code, DYB  
21 CFR 870.1340  
Class II  
Review Panel: Cardiovascular Devices

---

**Predicate Device(s):** *Primary:* K202141 Scorpion™ Portal Vein Access Set

---

**Description of the Device:** Each Portal Vein Access Set contains a 5F MPA catheter, a puncturing tool that comes in the following variations: 0.040" Stylet with a 5Fr Stylet Catheter (separated with a removable spacer clip) and a 14ga Stiffening Cannula with a 7F Cannula Sheath or 17ga Needle with a 6.2F Catheter (separated with a removable spacer clip) and a 13ga Stiffening Cannula with an 8F Cannula Sheath. The stiffening cannulas and the stylet/needle puncturing tools have curved distal ends, with directional handles that indicate the direction of the curves, which facilitate access into the hepatic vasculature and the creation of a pathway into the portal vein.

---

**Indication for Use:** The Scorpion Portal Vein Access Set is intended for transjugular liver access in diagnostic and interventional procedures.

---

**Device Modification:** The device modification included in this submission is limited to the removal of the following components from the SCORPION® Stylet Portal Vein Access Set and SCORPION® Needle Portal Vein Access Set:

- 10F Introducer sheath
- 10F Dilator

---

**Substantial Equivalence:** There is no change of intended use or fundamental scientific technology between the proposed modified and predicate device. The proposed modified device has the same indication for use as the predicate, K202141.

Non-Clinical Testing

In accordance with the Design Failure Modes and Effects Analysis, verification testing was identified to support the substantial equivalence of the modified Scorpion Portal Vein Access Set. The tests included:

- Functional Fit
- Hemostasis Leak
- Simulative Use (including component compatibility)

The following testing was leveraged from K202141:

- Performance Testing:
    - Radiopacity
    - Echogenicity
    - Corrosion Resistance
    - Dimensional & Functional Fit
    - Tensile Strength
    - Torque Strength Test
    - Liquid Leakage
    - Air Leakage
    - Burst Pressure
    - Flow Rate
    - Simulative Use - performance testing including dimensional, surface and compatibility of components
    - Luer Functional Testing
    - Shipping Test
    - Resistance to Fracture Testing
  - Biocompatibility
    - Cytotoxicity (ISO 10993-5)
    - Sensitization (ISO 10993-10)
-

- 
- Intracutaneous Irritation (ISO 10993-10)
  - Acute Systemic Toxicity (ISO 10993-11)
  - Material Mediated Pyrogen (ISO 10993-11)
  - Hemocompatibility (ISO10993-4)
    - ASTM Hemolysis – Direct and Indirect Contact
    - Complement Activation, SC5b-9
    - In Vivo Thrombogenicity
    - Platelet and Leucocyte counts
    - Partial Thromboplastin Time (PTT)

Animal testing was not required for the determination of substantial equivalence.

Clinical testing was not required for the determination of substantial equivalence.

Test results demonstrate that all acceptance criteria were met; therefore, the device meets the established product specifications.

---

**Conclusion:** The proposed device modifications to the Scorpion Portal Vein Access Set do not change its intended use or principles of operation. Based on the Indication for Use, design, and safety and performance testing, the Scorpion Portal Vein Access Set meets the requirements for its intended use and is substantially equivalent to the predicate device.

---